CN100586960C - HAb18GC2 monoclonal antibody and its light and heavy chain variable area genes, and application - Google Patents
HAb18GC2 monoclonal antibody and its light and heavy chain variable area genes, and application Download PDFInfo
- Publication number
- CN100586960C CN100586960C CN200710007452A CN200710007452A CN100586960C CN 100586960 C CN100586960 C CN 100586960C CN 200710007452 A CN200710007452 A CN 200710007452A CN 200710007452 A CN200710007452 A CN 200710007452A CN 100586960 C CN100586960 C CN 100586960C
- Authority
- CN
- China
- Prior art keywords
- hab18gc2
- monoclonal antibody
- gene
- chain variable
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to monoclonal antibody HAb18GC2 and its variable area gene of its heavy chain and light chain and polypeptide, and their uses in preparing therapeutic agent for reversinghepatic fibrosis etc. matrix deposition disease. The present monoclonal antibody HAb18GC2 can bind specificly with antibody HAb18G/CD147 highly expressed in human liver fibrosis tissue and with liverastrocyte and possesses function of facilitating MMPs secretion and reducing the extracellular matrix. The antibody light, heavy chain variable area genes are successfully cloned in the present invention and small molecule gene engineered antibodies of all kinds are constructed and expressed based on the gene for preparing drug for reversing liver fibrosis matrix deposition-related disease. The polypeptide coded by the present gene can crosslink with multiple effector molecule and prepare drug for reversing liver fibrosis matrix deposition-related disease.
Description
Technical field
The present invention relates to biotechnology and cell engineering field, particularly monoclonal antibody HAb18GC2 and heavy chain thereof, chain variable region gene, by the application of the polypeptide of described genes encoding and above-mentioned monoclonal antibody and light, heavy chain variable region gene, polypeptide.
Background technology
Hepatic fibrosis is various chronic hepatopathys to the common pathological change of liver cirrhosis development and must be through approach.Chronic hepatopathy mainly comprises various viral hepatitis, especially hepatitis C and hepatitis B.Whole world HbsAg carrier surpasses 2.8 hundred million.China is the high popular district of hepatitis B, its HbsAg carrier 1.3 hundred million, and hepatitis B patient surpasses 3,000 ten thousand, has the hepatitis B patient of 25-40% to cause liver cirrhosis, liver cancer, and its death toll was 400,000 people/years, had become China's serious social concern.Therefore control and reverse hepatic fibrosis become the key link that reduces liver problem sufferer's mortality ratio.Various chronic hepatopathys at first cause hepatic fibrosis, develop into liver cirrhosis then.Based on the application of Ultrastructural research of liver in recent years and molecular biotechnology, anthropogenetic hepatic fibrosis and even liver cirrhosis can reverse fully.Late international hepatopathy expert Hans Popper once asserted " who can stop hepatic fibrosis, and who just can cure most of hepatopathys ".
Liver cancer related antigen HAb18G is a kind of membrane protein molecule of high glycosylation.Anti-human monoclonal antibodies HAb18 by the preparation of my chamber oneself screens from liver cancer cDNA library and has obtained its cDNA sequence, inquiry Genbank confirms that itself and CD147 molecule cDNA sequence open reading frame are in full accord, with matrix metalloproteinase inductor EMMPRIN (Extrcellular Matrix metalloproteinase Inducer), Basigin etc. be same molecule.Functional study shows that HAb18G/CD147 can stimulate human fibroblasts's extracellular proteinase, degraded basilar membrane and intercellular substance.Known, HAb18G/CD147 is high expression level in the fibrosis tissue, especially the most remarkable with the hepatic fibrosis tissue expression, it is positioned the bile duct epithelial cell of breeding in liver cell and the hepatic fibrosis matrix, the equal high expression level of HAb18G/CD147 in the hepatic fibrosis pathology that HCV (hepatitis C virus), AIH (autoimmune hepatitis), HBV (hepatitis B virus), PBC (primary biliary cirrhosis) cause.These characteristics demonstrate this molecule and played the part of important role in the pathology processes of hepatic fibrosis, and it may MMPs be relevant with stimulating hepatic parenchymal cells, hepatic stellate cell secretion.
MMPs has the effect of ECM compositions such as each Collagen Type VI of degraded, proteoglycan, TIMPs is a MMPs specific tissue supressor, transcribing with active of TIMPs and MMPs can be subjected to multifactor and multilevel adjusting in the body, if the balance disorder then corresponding pathological state can occur.Many scholars find, expression amount and active decline of MMPs in the model of the hepatic fibrosis of the mankind's chronic hepatopathy and mouse, have all been observed, and the expression of TIMPs significantly increases, and in the whole process of hepatic fibrosis development, continue to exist, the over-deposit of prompting liver matrix is the main pathological characters of hepatic fibrosis progress.And in the decubation of hepatic fibrosis, with the feature that reverts to of the degraded of fibrous matrix and normal liver tissue.
The therapeutic advance of current hepatic fibrosis is: alleviate Fibrotic degree, delay of progression reverses the pathology process, but does not still have specific treatment means at hepatic fibrosis itself.As the peptide receptoroid antagonist of transforminggrowthfactor-(TGF-β 1),, can cause the undesirable actions such as degeneration of autoimmune disorder and cell after the use because its acceptor extensively is present in the various types of cells.Other as endothelin-receptor antagonists, prolyl hydroxylase inhibitors etc. all research among, the pharmacodynamic result that Shang Weiyou is clear and definite.
Summary of the invention
One object of the present invention is to prepare the monoclonal antibody HAb18GC2 at the HAb18G/CD147 extracellular region of high specific, and monoclonal antibody HAb18GC2 heavy chain and chain variable region gene and encoded polypeptide thereof are provided.These products can be used to carry out the functional study of HAb18G/CD147 molecule.
Another object of the present invention is with above-mentioned HAb18GC2 monoclonal antibody or its heavy chain and chain variable region gene or encoded polypeptide, perhaps reassemble into genetic engineering antibody, antibody fusion protein or protein conjugate, the derivative etc. of various ways, be used to prepare the medicine that reverses apposition relative diseases such as hepatic fibrosis.
According to an aspect of the present invention, the preparation, evaluation, the purifying that relate to monoclonal antibody HAb18GC2.The inventor is an immunogen with the extracellular region protein of the HAb18G/CD147 of high expression level in the hepatic fibrosis tissue, adopt the hybridoma technology preparation and filter out the hybridoma cell strain HAb18GC2 of stably excreting mouse-anti people HAb18G/CD147 extracellular region monoclonal antibody, be called HAb18Gedomab2 again (through Chinese typical culture collection center accession designation number on December 13rd, 2006: CCTCC-C200636).Its chromosome number is at 58-126, and mode 81-103, secreted antibody subtype are IgG1.To collect ascites behind its inoculation homology mouse peritoneal.Adopt in method pair cell culture supernatant such as flow cytometry, immunohistochemical methods and the ascites excretory specific antibody to carry out affinity and identify, its result shows that HAb18GC2 organizes all with people's stellate cell (HSCs) and people's hepatic fibrosis and combines.Gained ascites obtains the HAb18GC2 monoclonal antibody of certain purity through the ion exchange chromatography purifying.
According to another aspect of the present invention, the clone who relates to monoclonal antibody HAb18GC2 heavy chain and chain variable region gene.The present invention uses the PCR primer of an Analysis of Nested Design, has successfully cloned light, the heavy chain variable region gene of this antibody from hybridoma cell strain HAb18GC2.Wherein said heavy chain variable region gene total length is 348bp, its nucleotide sequence as in the sequence table＜400〉1 shown in, its amino acid sequence coded as in the sequence table＜400〉3 shown in.Described chain variable region gene total length is 321bp, its nucleotide sequence as in the sequence table＜400〉2 shown in, its amino acid sequence coded as in the sequence table＜400〉4 shown in, confirm the mouse antibodies variable region that the equal codified of resulting heavy chain and chain variable region gene is correct by analysis.
According to another aspect of the present invention, reverse the application for the treatment of liver fibrosis agent as preparation with described monoclonal antibody HAb18GC2 or its recombinant protein or protein derivatives.
Heavy chain variable region gene or its encoded polypeptides product with described monoclonal antibody HAb18GC2 set out, and reassemble into various forms of genetic engineering antibodies or antibody derivatives, reverse the application for the treatment of liver fibrosis agent as preparation.
Chain variable region gene or its encoded polypeptides product with described monoclonal antibody HAb18GC2 set out, and reassemble into various forms of genetic engineering antibodies or antibody derivatives, reverse the application for the treatment of liver fibrosis agent as preparation.
Description of drawings
Fig. 1 is the karyotype figure of hybridoma cell strain HAb18GC2.
Fig. 2 is that the SDS-PAGE purity of monoclonal antibody HAb18GC2 is identified figure.
Fig. 3 is light for the monoclonal antibody HAb18GC2 for the RT-PCR amplification, the agarose gel electrophoresis figure of heavy chain variable region gene.
Fig. 4 is the order-checking collection of illustrative plates of monoclonal antibody HAb18GC2 heavy chain variable region gene.
Fig. 5 is the order-checking collection of illustrative plates of monoclonal antibody HAb18GC2 chain variable region gene.
Fig. 6 is the gelatinase spectrogram of monoclonal antibody HAb18GC2.
Fig. 7 wears theca cell figure for reorganization basement membrane degradation experiment.
Embodiment
1, the preparation of monoclonal antibody HAb18GC2 and evaluation.
Immunization method: get the heavy female BALB/C mice in the 18g left and right sides (this school animal center provides) in 8～10 ages in week, with the HAb18G/CD147 extracellular region protein is immunogenic, carry out routine immunization, adopt subcutaneous multi-point injection, 100 μ g/ only add incomplete freund adjuvant booster immunization every 2 weeks with same dose antigen, abdominal injection, detect how anti-tiring of mice serum before the cytogamy, high person's tail vein supplementary immunization 1 time again of tiring, dosage is the same.The myeloma cell line SP2/0 that after 3 days HAb18G/CD147 extracellular region protein mice immunized splenocyte and interior generation is obtained merges under the PEG-1500 effect with 5: 1 ratio, and fused cell is cultivated in the HAT selective medium.
The foundation of hybridoma cell strain: with HAb18G/CD147 extracellular region protein antigen, the indirect ELISA method screening positive clone is behind the continuous limiting dilution in positive hole 2～3 times. a large amount of amplifications and liquid nitrogen cryopreservation; Give the hybridoma of homology mouse peritoneal injection inoculation screening simultaneously, collect ascites behind 10～14d.Described HAb18GedC2 hybridoma cell strain karyomit(e) is at 58-126, mode 81-103, and referring to accompanying drawing 1, its secretion specific monoclonal antibody HAb18GC2.
Monoclonal antibody is identified: the situation that combines that further detects Hybridoma Cell Culture supernatant and ascites and people's stellate cell (HSCs-T6) film surface antigen with flow cytometry FACS; The SP immunohistochemical method detects HAb18GC2 ascites and combines with the specificity of people's hepatic fibrosis tissue; The mensuration of hybridoma cell strain HAb18GC2 culture supernatant and mouse ascites antibody titers.Hypotype is accredited as mouse IgG1.
The purification process of monoclonal antibody HAb18GC2: adopt cation exchange chromatography, promptly the SP Sepharose of FPLC system FF ion exchange chromatography carries out purifying to the crude extract of HAb18GC2 ascites.Elutriant A liquid: 0.02mol/L citrate buffer solution (pH5.4), B liquid: 0.02mol/L citrate buffer solution, 1mol/L sodium-chlor (pH5.4).Flow velocity 1ml/min.
The evaluation of target protein behind the purifying: adopt ELISA method and non-reduced polyacrylamide gel electrophoresis, concentrate gum concentration 5%, resolving gel concentration 10%, electrophoretic buffer is the Tris-glycine buffer of PH 8.3, referring to accompanying drawing 2,1 is HAb18GC2 ascites among the figure, and 2 are elution peak (being the monoclonal antibody HAb18GC2 of purifying).
2, the clone of light, the heavy chain variable region gene of monoclonal antibody HAb18GC2, analyze and recombinate.
Used cell strain is stably excreting monoclonal antibody HAb18GC2 hybridoma cell strain HAb18GC2, and its excretory antibody molecule hypotype is IgG1.
The clone of the variable region gene of anti-HAb18G/CD147 extracellular region protein monoclonal antibody HAb18GC2
Get the HAb18GC2 hybridoma (5 * 10 that is in logarithmic phase
6), adopt the guanidinium isothiocyanate single stage method to extract total RNA, take a morsel and carry out the quantitative and 1% denaturing formaldehyde agarose gel electrophoresis detection of ultraviolet spectrophotometer.Be random primer with Oligo (dT) 15 (Promega company) subsequently, cDNA first chain is synthesized in reverse transcription.Then, utilize above-mentioned pairing primer extension product Fd (about 736bp) and full-length light chains (about 731bp) behind LMP sepharose (1.5%) electrophoresis, cut glue and separate the target fragment.Behind gel-purified test kit (promega Inc) recovery purifying, gel electrophoresis identifies that referring to accompanying drawing 3, M is DL-2000Marker among the figure, and 1 is the HAb18GC2 heavy chain variable region gene, and 2 is the HAb18GC2 chain variable region gene.Afterwards with the purpose fragment cloning to the T carrier, sequencing analysis is referring to accompanying drawing 4,5.
Oligo (dT)
15(Promega company) is as follows for the reverse transcription scheme of random primer: add the total RNA of 1 μ g (2 μ L) in the 20 μ L reaction systems successively, 0.5ug random primer Oligo (dT)
15(1 μ L), 4ulMgCL
2(25mM) 2 μ L, 5 * dNTPs, 2 μ L, 10 * damping fluid, 0.5 μ L RNase inhibitor adds ThermoScript II AMV 15U (0.75 μ L), water is mended to 20 μ L, mixing, 42 ℃ of water-bath 1h boil 3min, reaction product place-20 ℃ standby.
The pcr amplification reflection is carried out according to a conventional method: with above-mentioned product is template, uses 1 counterweight strand primer and 1 pair of light, heavy chain variable region gene of light chain primer amplification antibody respectively.Reaction system is: template cDNA2.5ul, dNTP (each 0.4mM), 10 * Buffer 5ul, Ex Taq archaeal dna polymerase 1.25u, 5 ' end and 3 ' end each 5ul of primer (about 30pmol) add water to 50ul, mixing, instantaneous centrifugal after, add 1-2 drop of liquid paraffin, put on the PCR instrument and react.Reaction conditions: 94 ℃ of 1min, 54 ℃ of 1min, 72 ℃ of 1min, 35 circulations, last 72 ℃ are extended 10min.
Purpose fragment T carrier cloning order-checking scheme is as follows: with reclaiming after the PCR product gel electrophoretic separation, be connected into the pMD18-T carrier.The ligation system is: pMD18-T carrier 1ul, PCR product gel purifying heavy chain (or light chain) 3ul, deionized water 1ul, connect damping fluid 5ul, 4 ℃ are spent the night behind the mixing, transformed into escherichia coli JM109, the screening recombinant clone adopts the order-checking of universal sequencing primer thing then.
The HAb18GC2 monoclonal antibody variable region gene pcr amplification primer sequence of design is as follows:
Murine heavy chain V district 5 ' end primer
5’-GGGGATATCCACCATG(AG)ACTTCGGG(TC)T?GAG?CT(TG)GGT?TTT-3’
Murine heavy chain V district 3 ' end primer
5’-AGGCTTACTAGTACAATCCCTGGGCACAAT-3’
Mouse light chain V district 5 ' end draws
5’-GGGGATATCCACCATGGAG(AT)CACA(GT)(AT)CTCGGGTCTTT(GA)T?A-3’
Mouse light chain V district 3 ' end primer
5’-GCGCCGTCTAGAATTAACACTCATTCCTGTTGAA-3’
Sequential analysis shows, its VH gene and the IG germline gene HV6 IGHV6S1*01 of family dna homolog are the highest, number X03398 in IMGT, its VH gene and anti-Mus musculus VH10G1 mRNAfor anti-dsRNA (RDV-RNA) antibody are the homology the highest (NCBI:MUSIGKCLI) of AB050074.1 and Mouse IgMrearranged anti-Dns hybridoma VDJ 3region from family 606.The IGKV6-20*O1 dna homolog of its VL gene and IG germline gene KV6 family is the highest, numbers Y15981 in IMGT.Its VL gene and M.domesticus IgKvariable region (NCBI:MDIGKVAP) and Mus musculus clone A1B1anti-fluorescein immunoglobulin light (NCBI:AF137620) chain antibody gene homology are the highest.This explanation, resulting heavy chain and chain variable region gene are the gene of the correct mouse antibodies variable region of codified.
, heavy chain variable region gene light or polypeptide based on above-mentioned anti-hepatic fibrosis monoclonal antibody HAb18GC2 of being cloned into, adopt gene engineering method, can be built into the genetic engineering antibody medicine of various ways, also can reconstitute the fusion or the recombinant protein medicine of various ways, can be crosslinked the active proenzyme that changes of adjusted extracellular matrix or biological response modifier etc. as prodrug, to be used to reverse the experimental study and the clinical application of apposition relative disease such as hepatic fibrosis.
From light, heavy chain variable region gene of the present invention, the novel antibody that can reassemble into mainly contains following several form: (1) chimeric antibody.Be that C district with the V district of mouse MAb and people Ig is formed by connecting and is people-mouse chimeric antibody.Specificity and avidity that it has intactly kept mouse MAb have reduced untoward reactions such as HAMA simultaneously.(2) humanized antibody.Humanization modified at the variable region gene structure, comprise that CDR transplants, surface amino groups acid residue frosting, the exchange of skeleton district, the location keeps and the epi-position guiding is selected etc., thereby the mouse source property that has not only reduced the variable region has kept specificity and the avidity of mouse MAb simultaneously again.(3) small molecular antibody.Mainly contain by VH-CH1 and VL-C1 form Fab antibody, with a polypeptide (GLy4Ser)
3The single domain antibody that joint connects single-chain antibody that VH gene and VL gene form, be made up of with non covalent bond be combined into Fv fragment antibody, by VH or functional domain of VL VH and VL, the atom that constitutes by single CDR etc.(4) multivalence miniantibody.Mainly contain double-stranded antibody, (ScFv)
2, Flex miniantibody, LD miniantibody, F (ab ')
2, F (ab '), (ScFv) etc.(5) bi-specific antibody.Be the antibody that a class has dual specificity and dual-use function, claim bifunctional antibody again.(6) recombinant antibody fusion proteins.Gene fragments such as Fab or Fv, with having that other protein genes such as the toxin of non-antibody or enzyme are connected to form a kind of recombinant protein of specific biological activity guiding target site.(7) phage antibody.The V district gene of Ig is connected after transfecting host bacterium with last gene III of filobactivirus DNA or gene VIII, makes its fusion protein product at film surface outer casing protein expression Fab or ScFv.By this product is taken turns the affine absorption of related antigen more, therefrom wash in a pan and sift out required specific antibody.
With above-mentioned antibody or by the polypeptide deutero-antibody of its genes encoding is carrier, and crosslinked immune conjugate of the effector substance of various anti-appositions and forming or guiding prodrug mainly contain following several form: (1) antibody-matrix conditioning agent conjugate.The deposition that the matrix conditioning agent can be regulated extracellular matrix has separately obtained curative effect preferably with degraded.But owing to after in its input body part arrival effect target site is only arranged, its regulating effect is not in full use and toxic side effect.With matrix conditioning agent and monoclonal antibody coupling, carry it by monoclonal antibody and arrive the effect that target site is given full play to its matrix degradation, make the effect of these factors stronger, and more single-minded.(2) antibody targeted enzymolysis prodrug.The conjugate of antibody and drug specificity activating enzymes is injected in the body, inject prodrug behind the certain hour at interval, make it change into the medicine that high density has degrading activity at the fibrosis position, thus the matrix of degradation of cell external sediment fast and effeciently.(3) immunoliposome.The surface energy that MAb is coupled to liposome fully combines the characteristic of MAb and antigen-specific bonded guidance quality and lipid physical efficiency parcel high amount of drug together, and relevant medicine in the embedding then can improve drug targeting and curative effect again.
3, the extracorporeal biology functional experiment of monoclonal antibody HAb18GC2.
The experiment of gelatin zymogram: people's stellate cell (HSCs-T6) is cultured to logarithmic phase, uses 0.25% trysinization, with 10
5The density in/hole is inoculated in 96 orifice plates, cultivates 24h.Discard culture supernatant, change serum-free medium.Adding final concentration is the monoclonal antibody HAb18GC2 of 100 μ g/ml.And set up negative control hole.Collect the serum-free culture cell conditioned medium at 20h.With the gelatin is 8% separation gel and the 5% concentrated glue of substrate preparation certain volume, gets culture supernatant and sample buffer mixture, and last sample begins electrophoresis.After electrophoresis stops, glue is put into Triton X-100 solution renaturation, in the gelatinase incubation buffer, hatch.Dyeing, decolouring, observation, film making.Experimental result, referring to accompanying drawing 6,1 negative contrast among the figure, 2 is HAb18GC2.
Reconstituted basement membrane degradation experiment: on Millice11 cell inner membrance, add Matrigel glue, put to glue dried.With 2.5g/L trysinization HSC cell, centrifuge washing.Hang with the RPIM-1640 that contains 0.1%BSA, chamber in the adding, adding final concentration in last chamber simultaneously is the monoclonal antibody HAb18GC2 of 100 μ g/ml.In 24 orifice plates of the following chamber of cell, add 500 μ l chemoattractants.24 orifice plates are put into 37 ℃, cultivate 20h in the 5%CO2 incubator.Take out cell, discard nutrient solution, 95% ethanol is 25min fixedly, filter membrane HE dyeing, and gradient alcohol dehydration is wiped Matrigel glue and cell in the chamber, cutting-out filter membrane with cotton swab; Transparent back mounting.The cell count of counting film back side invasion and attack is counted 4 visuals field on the film at random under 40 * light microscopic, and its mean value is obtained in 3 parts of every cell countings, and test repeats 3 times.Experimental result is referring to accompanying drawing 7,1 negative contrast among the figure, and 2 is HAb18GC2.
To sum up, gelatin zymogram experimental result shows that HAb18GC2 antibody can promote the generation of MMP-9; The reconstituted basement membrane degradation experiment detects and to show, HAb18GC2 acts on the degraded that can promote basilar membrane behind the HSC.These presentation of results, HAb18GC2 monoclonal antibody have the potentiality that reverse apposition relative diseases such as hepatic fibrosis.
Sequence table
＜110〉Chen Zhinan
＜120〉light, the heavy chain variable region gene of HAb18GC2 monoclonal antibody and its, coded polypeptide and application
<160>4
<210>1
<211>348
<212>DNA
＜213〉mouse
<220>
<221>V_region
<222>(1)...(348)
<400>1
gaa?gtg?aag?ctt?gag?gag?tct?gga?gga?ggc?ttg?gtg?caa?cct?gga?gga 48
tcc?atg?aaa?ctc?tcc?tgt?gtt?gcc?tct?gga?ttc?act?ttc?agt?aac?ttc 96
tgg?atg?aac?tgg?gtc?cgc?cag?tct?cca?gag?aag?ggg?ctt?gag?tgg?gtt?144
gct?gaa?att?aga?ttg?aaa?tct?aat?aat?tat?gca?aca?cat?tat?gcg?gag?192
tct?gtg?aaa?ggg?agg?ttc?acc?atc?tca?aga?gat?gat?tcc?aaa?agt?agt?240
gtc?tac?ctg?cag?atg?aac?aac?tta?aga?act?gaa?gac?act?ggc?att?tat?288
tac?tgt?acc?agc?tat?gat?tac?gaa?tac?tgg?ggc?caa?ggg?act?ctg?gtc?336
acc?gtc?tct?gca 348
<210>2
<211>321
<212>DNA
＜213〉mouse
<220>
<221>V_region
<222>(1)...(321)
<400>2
aac?att?gta?atg?acc?caa?tct?ccc?aaa?tcc?atg?tcc?atg?tca?gtg?ggc 48
gag?agg?gtc?acc?ttg?agc?tgc?aag?gcc?agt?gag?aat?gtg?ggt?act?tat 96
gta?tcc?tgg?tat?caa?cag?aaa?cca?gag?cag?tct?cct?aaa?ctg?ctg?ata 144
tac?ggg?gca?tcc?aac?cgg?tac?act?ggg?gtc?ccc?gat?cgc?ttc?aca?ggc 192
agt?gga?tct?gca?aca?gat?ttc?act?ctg?acc?atc?agc?agt?gtg?cag?gct 240
gaa?gac?ctt?gca?gat?tat?cac?tgt?gga?cag?agt?tac?agc?tat?cca?ttc 288
acg?ttc?ggc?tcg?ggg?aca?aag?ttg?gaa?ata?aaa 321
<210>3
<211>116
<212>PRT
＜213〉mouse
<220>
<221>V_segment
<400>3
1 5 10 15
Glu?Val?Lys?Leu?Glu?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro?Gly
20 25 30
Gly?Ser?Met?Lys?Leu?Ser?Cys?Val?Ala?Ser?Gly?Phe?Thr?Phe?Ser
35 40 45
Asn?Phe?Trp?Met?Asn?Trp?Val?Arg?Gln?Ser?Pro?Glu?Lys?Gly?Leu
50 55 60
Glu?Trp?Val?Ala?Glu?Ile?Arg?Leu?Lys?Ser?Asn?Asn?Tyr?Ala?Thr
65 70 75
His?Tyr?Ala?Glu?Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp
80 85 90
Asp?Ser?Lys?Ser?Ser?Val?Tyr?Leu?Gln?Met?Asn?Asn?Leu?Arg?Thr
95 100 105
Glu?Asp?Thr?Gly?Ile?Tyr?Tyr?Cys?Thr?Ser?Tyr?Asp?Tyr?Glu?Tyr
110 115
Trp?Gly?Gln?Gly?Thr?Leu?Val?Thr?Val?Ser?Ala
<210>4
<211>107
<212>PRT
＜213〉mouse
<220>
<221>V_segment
<400>4
1 5 10 15
Asn?Ile?Val?Met?Thr?Gln?Ser?Pro?Lys?Ser?Met?Ser?Met?Ser?Val
20 25 30
Gly?Glu?Arg?Val?Thr?Leu?Ser?Cys?Lys?Ala?Ser?Glu?Asn?Val?Gly
35 40 45
Thr?Tyr?Val?Ser?Trp?Tyr?Gln?Gln?Lys?Pro?Glu?Gln?Ser?Pro?Lys
50 55 60
Leu?Leu?Ile?Tyr?Gly?Ala?Ser?Asn?Arg?Tyr?Thr?Gly?Val?Pro?Asp
65 70 75
Arg?Phe?Thr?Gly?Ser?Gly?Ser?Ala?Thr?Asp?Phe?Thr?Leu?Thr?Ile
80 85 90
Ser?Ser?Val?Gln?Ala?Glu?Asp?Leu?Ala?Asp?Tyr?His?Cys?Gly?Gln
95 100 105
Ser?Tyr?Ser?Tyr?Pro?Phe?Thr?Phe?Gly?Ser?Gly?Thr?Lys?Leu?Glu
Ile?Lys
Claims (3)
1, the monoclonal antibody HAb18GC2 of the anti-HAb18G/CD147 extracellular region protein of a strain, it is characterized in that: by producing with specific hybridoma cell strain HAb18G edomab2 prepared behind the HAb18G/CD147 protein molecular extracellular region immune mouse, described hybridoma cell strain HAb18G edomab2 on December 13rd, 2006 by China's typical culture collection center preservation, its preservation accession designation number is: CCTCC-C200636.
2, the gene of monoclonal antibody HAb18GC2 as claimed in claim 1, it is characterized in that: comprise heavy chain variable region gene and chain variable region gene, the nucleotide sequence of described heavy chain variable region gene is shown in SEQ ID NO:1, and the nucleotide sequence of chain variable region gene is shown in SEQ ID NO:2.
3, monoclonal antibody HAb18GC2 as claimed in claim 1 reverses the application for the treatment of liver fibrosis agent as preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710007452A CN100586960C (en) | 2006-06-23 | 2007-01-16 | HAb18GC2 monoclonal antibody and its light and heavy chain variable area genes, and application |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610043014.7 | 2006-06-23 | ||
| CN200610043014 | 2006-06-23 | ||
| CN200710007452A CN100586960C (en) | 2006-06-23 | 2007-01-16 | HAb18GC2 monoclonal antibody and its light and heavy chain variable area genes, and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101054416A CN101054416A (en) | 2007-10-17 |
| CN100586960C true CN100586960C (en) | 2010-02-03 |
Family
ID=38794488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710007452A Active CN100586960C (en) | 2006-06-23 | 2007-01-16 | HAb18GC2 monoclonal antibody and its light and heavy chain variable area genes, and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100586960C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020119424A1 (en) | 2018-12-14 | 2020-06-18 | 中国药科大学 | Composition containing sumo inhibitor and application |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011042548A1 (en) * | 2009-10-09 | 2011-04-14 | Sanofi-Aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| CN104278013B (en) * | 2013-09-02 | 2017-02-15 | 武汉谐康科技有限公司 | Anti-human tissue transglutaminase 2 monoclonal antibody and application thereof |
| CN103622938B (en) * | 2013-11-14 | 2015-08-19 | 陈志南 | 3-{2-[([1,1 '-biphenyl]-4-methyl) amino]-1-ethoxy } the antitumor application of phenol |
| CN105820250B (en) * | 2016-04-29 | 2019-04-30 | 中国人民解放军第四军医大学 | A kind of anti-BASIGIN humanized antibody and its application |
| CN105999294A (en) * | 2016-05-12 | 2016-10-12 | 上海柏运医疗器材有限公司 | CD147 targeting drug-delivery system and preparation and application thereof |
| CN110642947B (en) * | 2019-08-27 | 2023-07-28 | 中国人民解放军第四军医大学 | Anti-human CD147 monoclonal antibody, expression vector, cell strain and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1782077A (en) * | 2004-06-14 | 2006-06-07 | 陈志南 | HAb18Gedomab 1 monoclonal antibody and its light and heavy chain variable area genes, coding polypeptide and use |
-
2007
- 2007-01-16 CN CN200710007452A patent/CN100586960C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1782077A (en) * | 2004-06-14 | 2006-06-07 | 陈志南 | HAb18Gedomab 1 monoclonal antibody and its light and heavy chain variable area genes, coding polypeptide and use |
Non-Patent Citations (8)
| Title |
|---|
| HAb18G/CD147拮抗肽的筛选及对肝癌细胞侵袭力的抑制. 黄宝成等.中华肿瘤杂志，第25卷第2期. 2003 |
| HAb18G/CD147拮抗肽的筛选及对肝癌细胞侵袭力的抑制. 黄宝成等.中华肿瘤杂志，第25卷第2期. 2003 * |
| 不同免疫方案制备抗HAb18G/CD147胞外区多克隆抗血清的比较. 张思河等.细胞与分子免疫学杂志，第21卷第1期. 2005 |
| 不同免疫方案制备抗HAb18G/CD147胞外区多克隆抗血清的比较. 张思河等.细胞与分子免疫学杂志，第21卷第1期. 2005 * |
| 抗人HAb18G/CD147胞外区蛋白单抗的制备及功能研究. 叶卉.第四军医大学学位论文. 2005 |
| 抗人HAb18G/CD147胞外区蛋白单抗的制备及功能研究. 叶卉.第四军医大学学位论文. 2005 * |
| 稳定表达肝癌相关抗原HAb18G/CD147 成纤维细胞株的建立及其意义. 黄勇等.第四军医大学学报，第25卷第8期. 2004 |
| 稳定表达肝癌相关抗原HAb18G/CD147 成纤维细胞株的建立及其意义. 黄勇等.第四军医大学学报，第25卷第8期. 2004 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020119424A1 (en) | 2018-12-14 | 2020-06-18 | 中国药科大学 | Composition containing sumo inhibitor and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101054416A (en) | 2007-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11291720B2 (en) | Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses | |
| WO2018068652A1 (en) | Anti-egfr and anti-cd3 bispecific antibody and applications thereof | |
| JP7262597B2 (en) | Bispecific antibodies and methods of making and using the same | |
| CN100586960C (en) | HAb18GC2 monoclonal antibody and its light and heavy chain variable area genes, and application | |
| WO2017201766A1 (en) | Anti-human pd-1 humanized monoclonal antibody and use thereof | |
| EP0617126A2 (en) | Polypeptide capable of inhibiting the binding bewteen human IL-6 and its receptor | |
| CN108456251A (en) | Anti- PD-L1 antibody and its application | |
| EP4039702A1 (en) | Anti-b7-h3 antibody and application thereof | |
| CN102321173A (en) | Humanized macrophage inhibitory factor 1 monoclonal antibody and application thereof | |
| CN109776678A (en) | A kind of humanization PD-L1 monoclonal antibody, preparation method and application | |
| CN102369219A (en) | Antibodies against human tweak and uses thereof | |
| CN107207608A (en) | Bispecific antibody, preparation method and use | |
| JP2022521850A (en) | Anti-alpha beta TCR-binding polypeptide with reduced fragmentation | |
| KR20230171465A (en) | Anti-CLDN4-anti-CD137 bispecific antibody | |
| CN101701039A (en) | Variable regions of light chains and heavy chains of FMU-EPCAM-2A9 monoclonal antibodies | |
| CN105916883B (en) | Bifunctional fusion proteins and its preparation method and application | |
| CN100480388C (en) | HAb18Gedomab 1 monoclonal antibody and light and heavy chain variable area genes, coding polypeptide and use | |
| CN106008708B (en) | A kind of monoclonal antibody and purposes of viruses of human hepatitis B's X protein | |
| CN101619305B (en) | Antihuman CD52 monoclonal antibody hybridoma cell line, monoclonal antibody, engineered antibody, carrier, reagent kit and application thereof | |
| CN111944047A (en) | anti-BCMA humanized single-chain antibody and application thereof | |
| CN104558181A (en) | Humanized single-chain variable fragments of targeted B lymphoma cells | |
| CN111848806B (en) | EGFR-CD3 bifunctional antibody and application thereof | |
| TW202241955A (en) | Garp protein antibody and application thereof | |
| CN114920842B (en) | Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof | |
| WO2023236968A1 (en) | Cd39/cd73 bispecific antigen binding protein and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160225 Address after: 710032 Changle West Road, Shaanxi, China, No. 169, No. Patentee after: The Fourth Military Medical University of the Chinese People's Liberation Army Address before: 710032 center of cell engineering, The Fourth Military Medical University, 17 West Changle Road, Xi'an, Shaanxi Patentee before: Chen Zhinan |